IgG and IgM anti-PP1Pk antibodies of human sera from p individuals were examined for their ability to agglutinate red blood cells (RBC) of various P phenotypes and to mediate ADCC of these RBC by human effector cells. Agglutinating antibodies were found in either the IgG or the IgM fraction, while ADCC active antibodies were found mainly in the IgG fraction and were essentially cytotoxic with Pk RBC. The possible relationship of these antibodies with early abortions of p mothers is discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0090-1229(83)90163-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Managing blood requirement in a rare P-null phenotype patient during the COVID pandemic in a resource-limited setting.
Asian J Transfus Sci
September 2022
Department of Paediatric Neurosurgery and Craniofacial Surgery, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham University, Kochi, Kerala, India.
We report the case of a 5-year-old girl with a rare P-null phenotype who presented for a neurosurgical procedure at our center. The case is unique as this patient was one of the two P-null phenotype cases reported in India and we report how we could successfully arrange a rare blood unit for her. As it was challenging to find a donor for her, autologous blood was collected.
View Article and Find Full Text PDFSuccessful management of maternal anti-PP1P alloimmunization in pregnancy with therapeutic plasma exchange and intravenous immunoglobulin.
J Clin Apher
June 2024
Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Anti-PP1P alloimmunization is rare given ubiquitous P1PK expression. Prevention of recurrent miscarriages and hemolytic disease of the fetus and newborn (HDFN) in pregnant individuals with anti-PP1P antibodies has relied upon individual reports. Here, we demonstrate the successful management of maternal anti-PP1P alloimmunization in a 23-year-old, G2P0010, with therapeutic plasma exchange (TPE), intravenous immunoglobulin (IVIG), and monitoring of anti-PP1P titers.
View Article and Find Full Text PDFManaging a Pregnancy in the Presence of the Rare Blood Group Antibody PP1Pk.
Womens Health Rep (New Rochelle)
April 2024
Gynecology and Obstetrics Service, Girona, Spain.
Pregnant women with p phenotype, who lack antigens P, P1, and Pk, spontaneously form anti-PP1Pk antibodies whose primary target is the placenta. The risk of miscarriage in these women is 50%-70% and reaches 87% in the second trimester. The therapies aim to reduce the titer of antibodies early in pregnancy.
View Article and Find Full Text PDFTreatment with plasma exchange of a pregnant woman with anti-PP1Pk alloimmunization: A case report.
Transfus Apher Sci
April 2024
UOC Medicina Trasfusionale, Ospedale del Mare, ASL Napoli 1 Centro, Italy.
The histo-blood group antigens P, P1 and Pk are a closely related set of glycosphingolipid structures expressed by red blood cells and other tissues. None of these three characters is expressed on p cells, a null phenotype that arises in the context of homozygous mutation of the A4GALT gene. Subjects with p phenotype spontaneously develop a natural alloantibody named anti-PP1Pk, which is a mixture of IgG and IgM against P1, P and Pk.
View Article and Find Full Text PDF[Serological characteristics and molecular mechanism of an individual with p phenotype].
Zhonghua Yi Xue Yi Chuan Xue Za Zhi
March 2023
Laboratory Department, Jiaxing Blood Center, Jiaxing, Zhejiang 314033, China.
Objective: To analyze the serological characteristics and molecular mechanism for an individual with p phenotype.
Methods: An individual with p phenotype upon blood group identification at Jiaxing Blood Center in May 2021 was analyzed. ABO, RhD and P1PK blood groups and irregular antibodies in her serum were identified using conventional serological methods.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!